Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?

Subbiah, Vivek; Gan, Boyi

doi:10.1158/1078-0432.CCR-22-1257

Vivek Subbiah

0000-0002-6064-6837

;

Vivek Subbiah *

1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

2Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

3MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, Texas.

*Corresponding Authors: Vivek Subbiah, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-563-1930; Fax: 713-792-0334; E-mail: vsubbiah@mdanderson.org; and Boyi Gan, bgan@mdanderson.org

Search for other works by this author on:

This Site

PubMed

Google Scholar

Boyi Gan

0000-0001-8884-6040

Boyi Gan *

4Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Clin Cancer Res 2022;28:3408–10

Received: May 01 2022

Revision Received: May 13 2022

Accepted: May 23 2022

Online Issn: 1557-3265

Print Issn: 1078-0432

Funding

Funding Group:

Award Group:
- Funder(s):
  NIH
- Award Id(s):
  R01CA242845
Award Group:
- Funder(s):
  Cancer Prevention and Research Institute of Texas
- Award Id(s):
  RP1100584
Award Group:
- Funder(s):
  Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
- Award Id(s):
  1U01 CA180964
Award Group:
- Funder(s):
  NCATS
- Award Id(s):
  UL1 TR000371
Award Group:
- Funder(s):
  MD Anderson Cancer Center
- Award Id(s):
  P30 CA016672
Award Group:
- Funder(s):
  University of Texas MD Anderson Cancer Center
Award Group:
- Funder(s):
  National Institutes of Health
- Award Id(s):
  R01CA181196
  ,
  R01CA244144
  ,
  R01CA247992
Award Group:
- Funder(s):
  Cancer Prevention & Research Institute of Texas
- Award Id(s):
  RP220258

2022

American Association for Cancer Research

Clin Cancer Res (2022) 28 (16): 3408–3410.

https://doi.org/10.1158/1078-0432.CCR-22-1257

Summary

Understanding metabolic dependencies and their therapeutic vulnerabilities is key to precision oncology. Malic enzyme 1 (ME1) is frequently overexpressed in cancers with protumorigenic effects. In contrast, consistent loss of ME1 expression in synovial sarcoma compared with other sarcomas indicates a unique ferroptosis liability for precision therapy in this form of cancer.

2022

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?

Summary

Citing articles via

Email alerts

AACR Journals

Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?

Summary

Sign in

Client Account

Sign in via your Institution

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only